Keymed Biosciences Inc. (HKEX: 02162) has licensed its approved IL-4Rα monoclonal antibody stapokibart (Kangyueda) to Singapore-based Aeira Pte. Ltd. for marketing registration and commercialization across 18 countries and regions in Southeast Asia and Central Asia — extending the drug's geographic footprint beyond China for the first time under a dedicated regional partner.
Under the agreement, Aeira takes on full responsibility for registration filings and commercialization across 11 Southeast Asian markets including Indonesia, Vietnam, Thailand, Malaysia and the Philippines, five Central Asian countries, and the Hong Kong and Macao special administrative regions. Keymed retains manufacturing and product supply obligations. Financial terms were not disclosed, though the announcement confirms an upfront payment, country-level regulatory approval milestones, commercialization milestones, and royalties described as up to a "high double-digit percentage" of net sales in the licensed territory.
The deal is structured as a pure commercialization license on an already-approved asset rather than a development partnership — a structurally distinct transaction type from Keymed's larger Western-market deals. Stapokibart received China's National Medical Products Administration (NMPA) approval for moderate-to-severe atopic dermatitis in September 2024, for chronic rhinosinusitis with nasal polyposis in December 2024, and for seasonal allergic rhinitis in February 2025. Phase III data for the allergic rhinitis indication were subsequently published in Nature Medicine.